Opportunity for catch-up HPV vaccination in young women after first delivery

Journal of Epidemiology and Community Health

Volumn 64, Issue 7, 2010, Pages 610-615

  Rama, Cristina Helena ^a,b   Villa, Luisa L ^c   Pagliusi, Sonia ^d   Andreoli, Maria A ^c   Costa, Maria C ^c   Thomann, Patricia ^e   Alves, Venancio A F ^b   Longatto Filho, Adhemar ^f,g   Eluf Neto, Jose ^b  

^a HOSPITAL MATERNIDADE LEONOR MENDES DE BARROS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^e Qiagen do Brasil   (Brazil)

^f UNIVERSITY OF MINHO   (Portugal)

^g INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

AGE STRUCTURE; CANCER; DISEASE PREVALENCE; HOSPITAL SECTOR; MATERNAL HEALTH; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; REPRODUCTIVE HEALTH; RISK FACTOR; SMOKING; VACCINATION; VIRAL DISEASE;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; ARTICLE; BRAZIL; CROSS-SECTIONAL STUDY; FEMALE; GENETICS; HUMAN; MATERNAL AGE; PAPILLOMAVIRUS INFECTION; PARITY; POVERTY; PREGNANCY; PREVALENCE; PUERPERIUM; RISK FACTOR; TIME; VAGINA SMEAR; VIROLOGY;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; BRAZIL; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; HUMANS; MATERNAL AGE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PARITY; POSTPARTUM PERIOD; POVERTY; PREGNANCY; PREVALENCE; RISK FACTORS; TIME FACTORS; VAGINAL SMEARS; YOUNG ADULT;

BRAZIL; SAO PAULO [BRAZIL];

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 77955651095     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech.2008.086439     Document Type: Article

References (37)

1. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
2. Instituto Nacional de Câncer (INCA). Coordenação de Prevenção e Vigilância. Estimativa 2008. Rio de Janeiro: Incidência de Câncer no Brasil, 2008. http://www.inca.gov.br/ estimativa/2008/versaofinal.pdf.
3. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004;324:17-27.
4. Muñoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
5. Perez G, Lazcano-Ponce E, Hernandez-Avila M, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-likeparticle vaccine in Latin American women. Int J Cancer 2008;122:1311-18.
6. Paavonen J, Jenkins D, Bosch FX, et al. HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind randomised controlled trial. Lancet 2007;369:2161-70.
7. Markowitz LE, Dunne EF, Saraiya M, et al. Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24.
8. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53.
9. Opel DJ, Diekema DS, Marcuse EK. A critique of criteria for evaluating vaccines for inclusion in mandatory school immunization programs. Pediatrics 2008;122:504-10.
10. Drain PK, Holmes KK, Hughes JP, et al. Determinants of cervical cancer rates in developing countries. Int J Cancer 2002;100:199-205.
11. Chan PK, Chang AR, Tam WH, et al. Prevalence and genotype distribution of cervical human papillomavirus infection: comparison between pregnant women and nonpregnant controls. J Med Virol 2002;67:583-8.
12. Smith EM, Ritchie JM, Yankowitz J, et al. HPV prevalence and concordance in the cervix and oral cavity of pregnant women. Infect Dis Obstet Gynecol 2004;12:45-56.
13. Takakuwa K, Mitsui T, Iwashita M, et al. Studies on the prevalence of human papillomavirus in pregnant women in Japan. J Perinat Med 2006;34:77-9.
14. Syrjanen K, Naud P, Derchain S, et al. Comparing Pap smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study. Anticancer Res 2005;25:3469-80.
15. Solomon D, Davey D, Kurman R, et al. Forum Group. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-19.
16. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
17. McCullagh P, Nelder JA. Generalized linear models. 2nd edn. New York: Chapman and Hall, 1989.
18. BreslowNE, Day NE. Statistical methods in cancer research. Vol I. The analysis of casecontrol studies. Publ. no. 32. Lyon: International Agency for Research on Cancer, 1980.
19. StataCorp. Stata statistical software: Release 8.2. College Station, TX: Stata Corporation, 2003.
20. Sanjose S, Almirall R, Lloveras B, et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003;30:788-93.
21. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005;191:1796-807.
22. Lazcano-Ponce E, Herrero R, Munoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001;91:412-20.
23. Thomas JO, Herrero R, Omigbodun AA, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004;90:638-45.
24. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-19.
25. Nonnenmacher B, Breitenbach V, Villa LL, et al. Genital human papillomavirus infection identification by molecular biology among asymptomatic women. Rev Saude Publica 2002;36:95-100.
26. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-23.
27. Rosa MI, Fachel JMG, Rosa DD, et al. Persistence and clearance of human papillomavirus infection: a prospective cohort study. Am J Obstet Gynecol 2008;199:617.e1-7.
28. Kahn JA, Rosenthal SL, Jin Y, et al. Rates of human papillomavirus vaccination, attitudes about vaccination and human papillomavirus prevalence in young women. Obstet Gynecol 2008;111:1103-10.
29. Banura C, Franceschi S, Doorn LJ, et al. Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis 2008;197:555-62.
30. Banura C, Franceschi S, van Doorn LJ, et al. Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. Int J Cancer 2008;123:2180-7.
31. Rama CH, Roteli-Martins CM, Derchain SF, et al. Prevalence of genital HPV infection among women screened for cervical cancer. Rev Saude Publica 2008;42:123-30.
32. Hernández-Girón C, Smith JS, Lorincz A, et al. High-risk human papillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico. Sex Transm Dis 2005;32:613-18.
33. Agência Nacional de Vigilância Sanitária - ANVISA. Resolução no 2.777, de 24 de agosto de 2006. Vacina quadrivalente recombinante contra papilomavírus humanos. Ministério da Saúde 2006a. ftp://ftp.saude.sp.gov.br/ftpsessp/bibliote/informe- eletronico/2006/iels.dezembro.06/iels236/U-PT-MS-GM-3124-071206.pdf (accessed 21 December 2008).
34. Shin HR, Franceschi S, Vaccarella S, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004;190:468-76.
35. Vaccarella S, Herrero R, Snijders PJ, et al. IARC HPV Prevalence Surveys (IHPS) Study Group. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 2008;37:536-46.
36. Poppe WA, Peeters R, Drijkoningen M, et al. Cervical cotinine and macrophage-Langerhans cell density in the normal human uterine cervix. Gynecol Obstet Invest 1996;41:253-9.
37. Giuliano AR, Papenfuss M, Abrahamsen M, et al. Human papillomavirus infection at the United States-Mexico border. Cancer Epidemiol Biomarkers Prev 2001;10:1129-36.